SCHEMBL6182632

SCHEMBL6182632

CCOc1cccc(C(Br)C=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.46
CYP3A4 P08684 1/20 0.46
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPK1 P28482 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5312200 0.84 CYSLTR2 (0.53) TSHRTHRBCACNA1B
SCHEMBL11895862 0.82 TP53 (0.47) TP53CYP3A4CHRM2CHRM1CHRM3
SCHEMBL380929 0.81 CHRM2 (0.49) CYP3A4CHRM2CHRM1CHRM3ALDH1A1
SCHEMBL2420284 0.81 SLC22A12 (0.42) SMN1; SMN2TDP1
SCHEMBL16432400 0.80 MAOB (0.57) KDM4EALDH1A1SMN1; SMN2
SCHEMBL20703405 0.80 NQO1 (0.52) ALDH1A1TSHRTDP1ACACBACACA
SCHEMBL2949090 0.80 NQO1 (0.52) ALDH1A1TSHRTDP1ACACBACACA
SCHEMBL8045881 0.80 TP53 (0.52) TP53CYP3A4KDM4EALDH1A1SMN1; SMN2
SCHEMBL6202675 0.77 TP53 (0.46) TP53CYP3A4KDM4EALDH1A1SMN1; SMN2
SCHEMBL15568624 0.77 TSHR (0.39) KDM4EALDH1A1SMN1; SMN2MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 EP disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 US disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 TP53 376/4885CYP3A4 667/4885CHRM2 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.